Vertanical

Executive Summary

Vertanical is a Berlin-based biopharmaceutical company founded in 2018, dedicated to developing innovative therapies for chronic pain. Its lead asset, VER-01, is a cannabinoid-based medication designed to address pain along with associated symptoms such as sleep disorders and depressive moods. The company aims to establish VER-01 as a leading chronic pain therapy by 2030, targeting a large and underserved market where current treatments often have limited efficacy or significant side effects. Vertanical's focus on cannabinoid science positions it at the intersection of digital health and medical devices, leveraging novel mechanisms to improve patient outcomes. Currently, Vertanical is in Phase 3 clinical development for VER-01, a critical stage that will determine the drug's safety and efficacy profile. The company has not yet disclosed specific trial timelines, but successful completion could pave the way for regulatory submissions in major markets. With a private status and no publicly available financial data, Vertanical's valuation remains opaque. However, its progress in Phase 3 suggests meaningful pipeline maturation. Key upcoming catalysts include Phase 3 data readouts, potential strategic partnerships for commercialization, and regulatory milestones. The company's success hinges on demonstrating robust clinical benefits and navigating the evolving regulatory landscape for cannabinoid-based therapies.

Upcoming Catalysts (preview)

• H2 2026Phase 3 top-line results for VER-0170% success
• 2026Strategic partnership or licensing deal50% success
• 2027Regulatory submission initiation (EMA/FDA)60% success